These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21842338)

  • 1. CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.
    Choi CI; Kim MJ; Chung EK; Lee HI; Jang CG; Bae JW; Lee SY
    Eur J Clin Pharmacol; 2012 Feb; 68(2):149-54. PubMed ID: 21842338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population.
    Hong X; Zhang S; Mao G; Jiang S; Zhang Y; Yu Y; Tang G; Xing H; Xu X
    Eur J Clin Pharmacol; 2005 Oct; 61(9):627-34. PubMed ID: 16094537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.
    Bae JW; Choi CI; Lee HI; Lee YJ; Jang CG; Lee SY
    Int J Clin Pharmacol Ther; 2012 Sep; 50(9):683-9. PubMed ID: 22735459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients.
    Chen G; Jiang S; Mao G; Zhang S; Hong X; Tang G; Li Z; Liu X; Zhang Y; Xing H; Wang B; Yu Y; Xu X
    Methods Find Exp Clin Pharmacol; 2006; 28(1):19-24. PubMed ID: 16541193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic properties and bioequivalence of two irbesartan/ hydrochlorothiazide fixed-dose combination tablets in healthy male Chinese volunteers.
    Liu J; Wu L; Hu X; Wu G; Zheng Y; Zhou H; Zhai Y; Zhu M; ShenTu J
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):573-81. PubMed ID: 25828636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.
    Werner D; Werner U; Meybaum A; Schmidt B; Umbreen S; Grosch A; Lestin HG; Graf B; Zolk O; Fromm MF
    Clin Pharmacokinet; 2008; 47(5):323-32. PubMed ID: 18399713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.
    Li Z; Wang G; Wang LS; Zhang W; Tan ZR; Fan L; Chen BL; Li Q; Liu J; Tu JH; Hu DL; Liu ZQ; Zhou HH
    Xenobiotica; 2009 Oct; 39(10):788-93. PubMed ID: 19604036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.
    Choi CI; Kim MJ; Jang CG; Park YS; Bae JW; Lee SY
    Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):476-80. PubMed ID: 21726410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.
    Bae JW; Choi CI; Kim MJ; Oh DH; Keum SK; Park JI; Kim BH; Bang HK; Oh SG; Kang BS; Park HJ; Kim HD; Ha JH; Shin HJ; Kim YH; Na HS; Chung MW; Jang CG; Lee SY
    Acta Pharmacol Sin; 2011 Oct; 32(10):1303-8. PubMed ID: 21841812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.
    Yasar U; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML
    Clin Pharmacol Ther; 2002 Jan; 71(1):89-98. PubMed ID: 11823761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects.
    Jiang S; Mao G; Zhang S; Hong X; Tang G; Li Z; Liu X; Zhang Y; Wang B; Xu X; Wang X
    Clin Pharmacol Ther; 2005 Sep; 78(3):239-48. PubMed ID: 16153395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers.
    Wittayalertpanya S; Chariyavilaskul P; Prompila N; Sayankuldilok N; Eiamart W
    Int J Clin Pharmacol Ther; 2014 May; 52(5):431-6. PubMed ID: 24725445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of irbesartan in hypertensive children and adolescents.
    Sakarcan A; Tenney F; Wilson JT; Stewart JJ; Adcock KG; Wells TG; Vachharajani NN; Hadjilambris OW; Slugg P; Ford NF; Marino MR
    J Clin Pharmacol; 2001 Jul; 41(7):742-9. PubMed ID: 11452706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions.
    Huang XH; Li J; Qiu FR; Xie HT; Huang JH; Li JC; Zheng QS
    Eur J Drug Metab Pharmacokinet; 2006; 31(4):259-64. PubMed ID: 17315536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes.
    Bourrié M; Meunier V; Berger Y; Fabre G
    Drug Metab Dispos; 1999 Feb; 27(2):288-96. PubMed ID: 9929518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects.
    Marino MR; Langenbacher K; Ford NF; Uderman HD
    J Clin Pharmacol; 1998 Mar; 38(3):246-55. PubMed ID: 9549663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
    Hallberg P; Karlsson J; Kurland L; Lind L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
    J Hypertens; 2002 Oct; 20(10):2089-93. PubMed ID: 12359989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers.
    Vachharajani NN; Shyu WC; Mantha S; Park JS; Greene DS; Barbhaiya RH
    J Clin Pharmacol; 1998 May; 38(5):433-6. PubMed ID: 9602956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.
    Jeon JY; Im YJ; Kim Y; Han SM; Jo MJ; Shin DH; Yoo JS; Moon BK; Kim BK; Lee BH; Choi YH; Cho BS; Jang HY; Chae SW; Kim MG
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1296-9. PubMed ID: 23030309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.
    Yin OQ; Tomlinson B; Chow MS
    Clin Pharmacol Ther; 2005 Oct; 78(4):370-7. PubMed ID: 16198656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.